Tag:

Gilead Sciences

Latest Headlines

Latest Headlines

Gilead's Zydelig, J&J's Imbruvica will go toe-to-toe in EU with nod for CLL

Gilead Sciences, which this week got FDA approval for its new blood cancer drug Zydelig (idelalisib), has now gotten a recommendation for its use in Europe. But competitor Imbruvica from Johnson & Johnson, which got a head start in the U.S., also received a nod from EU authorities today.

Can Gilead break into cancer? With Zydelig approval, it gets its chance

Armed with a brand-new FDA approval for its blood cancer drug Zydelig (idelalisib), Gilead will take on the oncology market.

Pricey hep C drugs plus thrifty payers equal thorny consequences for patients

We've heard plenty from payers looking to limit access to Gilead Sciences' pricey new hepatitis C treatment Sovaldi. What's the downstream version of that story? Doctors frustrated by reimbursement rejections and patients denied access to a potential cure.

JAMA: Hep C drugs could add $300 to every American's insurance premium

The payer panic over the cost of Gilead Sciences' pricey-and-wildly-successful hepatitis C drug Sovaldi has been well documented. But now, one of the two biggest pharmacy benefits managers in the U.S. says the debate over Sovaldi's $1,000-per-pill price is a symptom of a bigger anxiety.

Gilead litigation says claims by Merck, AbbVie on Sovaldi are patently wrong

Gilead Sciences got to the market first with an interferon-free oral hepatitis C fighter, a category projected to hit $20 billion in sales by 2020. Its Sovaldi has been racking up unprecedented sales, and a raft of litigation, as other drugmakers look for a way to get a piece of that action.

Riled by $84,000 Sovaldi, Senate panel digs into Gilead's Pharmasset buy

Add a new set of pricing foes for Gilead Sciences). A U.S. Senate committee has joined the forces arrayed against the company's breakthrough hepatitis C drug Sovaldi and its $84,000 price tag.

FDA warns Gilead over 'misleading' paid search link

The drug is approved for treating--not preventing--hepatitis B, prompting FDA to call the advert misleading.

Which big brands will still be bringing in the big bucks in 2020?

Best-selling drugs did well for themselves in 2013, churning out more than $76 billion in sales. But big-name brands could stand the test of time and help the top 10 rake in more than $80 billion in 2020, according to a new report.

Bristol-Myers toes the next hep C frontier: a four-week cure

Gilead Sciences' Sovaldi has broken sales records thanks to its ability to cure hepatitis C with an effective, if costly, 12-week regimen. But rivals believe there's plenty of room in the market for a speedier solution, and Bristol-Myers Squibb plans to use its ex-partner's blockbuster to craft a four-week contender.

Why does Sovaldi cost $84,000? Gilead Sciences being pressed hard for an answer

Payers, politicians and some regulators have been balking at the $84,000 price tag on Gilead's hepatitis C treatment Sovaldi ever since it hit the market in January. Now two top member of Congress are demanding that the company appear at a congressional hearing to explain the product's high price.